학술논문
Polymorphisms associated with optimization of biological therapy through drug dose reduction in moderate‐to‐severe psoriasis.
Document Type
Article
Author
Source
Subject
*BIOTHERAPY
*DRUG therapy
*PSORIATIC arthritis
*PSORIASIS
*
*
*
Language
ISSN
0926-9959
Abstract
Polymorphisms associated with optimization of biological therapy through drug dose reduction in moderate-to-severe psoriasis We recruited 120 patients with moderate-to-severe plaque psoriasis from the Dermatology Department of "Hospital Universitario La Princesa" in Madrid treated with etanercept (52.5%), adalimumab (30.8%) and/or ustekinumab (16.7%) (Fig. a). 50/120 patients were subjected to a second biological drug cycle and 13 to a third cycle (total 183 cycles). New polymorphisms associated with response to anti-TNF drugs in patients with moderate-to-severe plaque psoriasis. [Extracted from the article]